Abstract
The idea of using the lytic power of viruses against malignant cells has been entertained for many decades. However, oncolytic viruses gained broad attention as an emerging anti-cancer therapy only recently with the successful implementation of several oncolytic viruses to treat advanced melanoma. Here we review the history of oncolytic viruses in the Russian Federation and recent biotechnological advances in connection with the perspectives of their practical use against aggressive tumors such as glioblastoma or pancreatic cancer. A particular emphasis is made on novel applications of safe non-lytic virus-derived vectors armed with prodrug-converting enzyme transgenes. Rational improvement of oncotropism by conjugation with biopolymers and nanoformu-lations is also discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 266-278 |
| Number of pages | 13 |
| Journal | Current Pharmaceutical Biotechnology |
| Volume | 24 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 2023 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- adeno-associated viruses
- adenoviruses
- enteroviruses
- enzyme gene therapy
- Gliomas
- pancreatic cancer
- parvoviruses
ASJC Scopus subject areas
- Biotechnology
- Pharmaceutical Science
Fingerprint
Dive into the research topics of 'Anti-cancer Virotherapy in Russia: Lessons from the Past, Current Challenges and Prospects for the Future'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS